Next Article in Journal
Are AMPA Receptor Positive Allosteric Modulators Potential Pharmacotherapeutics for Addiction?
Previous Article in Journal
A New Phenylpyrazoleanilide, Y-320, Inhibits Interleukin 17 Production and Ameliorates Collagen-Induced Arthritis in Mice and Cynomolgus Monkeys
Previous Article in Special Issue
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics
Pharmaceuticals 2014, 7(1), 18-28; doi:10.3390/ph7010018
Review

Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient

1,†
,
2,†
 and
2,*
1 Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, 736 Cambridge Street, Brighton, MA 02135, USA 2 Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street Suite 8E, Boston, MA 02115, USA These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 18 October 2013 / Revised: 16 December 2013 / Accepted: 24 December 2013 / Published: 30 December 2013
(This article belongs to the Special Issue Immunosuppressant Drugs)
View Full-Text   |   Download PDF [191 KB, 31 December 2013; original version 30 December 2013]

Abstract

Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.
Keywords: autoimmune liver disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; overlap syndrome autoimmune liver disease; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; overlap syndrome
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Abhyankar, A.; Tapper, E.; Bonder, A. Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. Pharmaceuticals 2014, 7, 18-28.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert